Frankfurt - Delayed Quote EUR

Corvus Pharmaceuticals, Inc. (C17.F)

Compare
4.7600
+0.0150
+(0.32%)
At close: January 30 at 8:12:27 AM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
25,094.0000
23,407.0000
32,565.0000
38,630.0000
43,760.0000
Operating Income
-25,094.0000
-23,407.0000
-32,565.0000
-38,630.0000
-43,760.0000
Net Non Operating Interest Income Expense
1,696.0000
1,584.0000
654.0000
-15.0000
540.0000
Other Income Expense
-33,435.0000
-5,206.0000
-9,396.0000
-4,596.0000
37,225.0000
Pretax Income
-56,833.0000
-27,029.0000
-41,307.0000
-43,241.0000
-5,995.0000
Net Income Common Stockholders
-56,833.0000
-27,029.0000
-41,307.0000
-43,241.0000
-5,995.0000
Diluted NI Available to Com Stockholders
-56,833.0000
-27,029.0000
-41,307.0000
-43,241.0000
-5,995.0000
Basic EPS
-0.99
-0.56
-0.89
-1.03
-0.20
Diluted EPS
-0.99
-0.56
-0.89
-1.03
-0.20
Basic Average Shares
56,147.4070
48,025.2740
46,553.5110
41,854.1100
29,478.8780
Diluted Average Shares
56,147.4070
48,025.2740
46,553.5110
41,854.1100
29,478.8780
Total Operating Income as Reported
-25,094.0000
-23,407.0000
-32,565.0000
-38,630.0000
-43,760.0000
Total Expenses
25,094.0000
23,407.0000
32,565.0000
38,630.0000
43,760.0000
Net Income from Continuing & Discontinued Operation
-56,833.0000
-27,029.0000
-41,307.0000
-43,241.0000
-5,995.0000
Normalized Income
-25,803.0000
-27,029.0000
-41,329.0000
-43,241.0000
-5,995.0000
Interest Income
--
--
--
--
540.0000
Interest Expense
--
--
--
15.0000
--
Net Interest Income
1,696.0000
1,584.0000
654.0000
-15.0000
540.0000
EBIT
-25,094.0000
-23,407.0000
-32,565.0000
-38,630.0000
-43,760.0000
EBITDA
-25,001.0000
-23,256.0000
-32,198.0000
-38,170.0000
-43,128.0000
Reconciled Depreciation
93.0000
151.0000
367.0000
460.0000
632.0000
Net Income from Continuing Operation Net Minority Interest
-56,833.0000
-27,029.0000
-41,307.0000
-43,241.0000
-5,995.0000
Total Unusual Items Excluding Goodwill
-31,030.0000
--
22.0000
--
--
Total Unusual Items
-31,030.0000
--
22.0000
--
--
Normalized EBITDA
6,029.0000
-23,256.0000
-32,220.0000
-38,170.0000
-43,128.0000
12/31/2020 - 3/30/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

42Z.F Revolution Medicines, Inc.
39.00
0.00%
 
2Q5.F Renovaro Inc.
0.6970
-8.77%
 
COGT Cogent Biosciences, Inc.
9.62
+3.44%
 
CKPT Checkpoint Therapeutics, Inc.
2.8400
0.00%